Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Taguchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Taguchi, H.
Mol Cancer Ther. 2006;5:2522-2530
© 2006 American Association for Cancer Research

Research Articles: Therapeutics, Targets, and Development

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

Takayuki Ikezoe1, Chie Nishioka1, Taizo Tasaka2, Yang Yang1, Naoki Komatsu1, Kazuto Togitani1, H. Phillip Koeffler3 and Hirokuni Taguchi1

1 Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi, Japan; 2 Department of Internal Medicine, Kagawa University, Kita-gun, Kagawa, Japan; and 3 Department of Hematology and Oncology, Cedars-Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, California

Requests for reprints: Takayuki Ikezoe, Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan. Phone: 81-88-880-2345; Fax: 81-88-880-2348. E-mail: ikezoet{at}med.kochi-u.ac.jp

Abstract

We studied antitumor effects of receptor tyrosine kinase inhibitor sunitinib (formerly SU11248) against a variety of hematologic malignancies including the following leukemias: eosinophilic (EOL-1), acute myeloid (THP-1, U937, Kasumi-1), biphenotypic (MV4-11), acute lymphoblastic (NALL-1, Jurkat, BALL-2, PALL-1, PALL-2), blast crisis of chronic myeloid (KU812, Kcl-22, K562), and adult T-cell (MT-1, MT-2, MT-4), as well as non-Hodgkin's lymphoma (KS-1, Dauji, Akata) and multiple myeloma (U266). Thymidine uptake studies showed that sunitinib was active against EOL-1, MV4-11, and Kasumi-1 cells, which possessed activating mutations of the PDGFR{alpha}, FLT-3, and c-KIT genes, respectively, with IC50s of <30 nmol/L. In addition, sunitinib inhibited the proliferation of freshly isolated leukemia cells from patients possessing mutations in FLT3 gene. Annexin V staining showed that sunitinib induced apoptosis of these cells. Sunitinib inhibited phosphorylation of FLT3 and PDGFR{alpha} in conjunction with blockade of mammalian target of rapamycin signaling in MV4-11 and EOL-1 cells, respectively. Interestingly, rapamycin analogue RAD001 enhanced the ability of sunitinib to inhibit the proliferation of leukemia cells and down-regulate levels of mammalian target of rapamycin effectors p70 S6 kinase and eukaryotic initiation factor 4E–binding protein 1 in these cells. Taken together, sunitinib may be useful for treatment of individuals with leukemias possessing activation mutation of tyrosine kinase, and the combination of sunitinib and RAD001 represents a promising novel treatment strategy. [Mol Cancer Ther 2006;5(10):2522–30]

Introduction

Class III and V receptor tyrosine kinases (RTK), including fms-like tyrosine kinase 3 (FLT3), c-KIT, platelet-derived growth factor receptor (PDGFR), and endothelial growth factor receptors (VEGFR), respectively, consist of five immunoglobulin-like domains in their extracellular regions and a juxtamembrane domain, a kinase domain interrupted by a kinase insertion domain, and a COOH-terminal domain in intracellular regions (1). On ligand binding, RTK activates its downstream effectors including protein kinase B/Akt, signal transducers and activators of transcription (STAT), and extracellular signal-regulated kinases (ERK)-1/2, leading to cell proliferation, differentiation, and/or survival (2, 3). Recent studies found that activating mutations of RTKs frequently occurred in acute myeloid leukemia (AML): internal tandem duplications (ITD) of the juxtamembrane domain of FLT3 (FLT3-ITD) has been found in 20% to 30% of the cases of de novo AML (4). Approximately 7% of cases of AML possessed D835 mutation, a point mutation in the activation loop of the second kinase domain of FLT3 (4). These mutations constitutively activate this receptor kinase without ligand binding, resulting in the activation of downstream prosurvival signals, and are associated with elevated blast counts, increased relapse rate, and poor overall survival (5–8). Mutations of c-KIT and PDGFR are also associated with subsets of AML (9–12) as well as gastrointestinal stromal tumors (GIST; refs. 13, 14). Thus, RTKs represent promising molecular targets for treatment of AML.

The serine/threonine kinase mammalian target of rapamycin (mTOR) is activated by phosphatidylinositol 3-kinase/Akt signaling and regulates cell proliferation, in part, by ribosomal protein translation and the initiation of cap-dependent translation (15, 16). mTOR phosphorylates p70 S6 kinase (p70S6K) and eukaryotic initiation factor 4E–binding protein 1 (4E-BP-1) and increases the translation of mRNAs with long, highly structured 5'-untranslated regions, such as cyclin D1 and c-Myc, which regulate cell cycle transition from G1 to S phase (15, 16). The mTOR inhibitors, rapamycin or its analogue RAD001, have been shown to be active against many types of solid tumors, as well as subsets of leukemia, and are now being used in clinical trials (17).

Sunitinib (formerly SU11248) is a novel, orally available, multitargeted receptor tyrosine kinase inhibitor with selectivity against FLT3, c-KIT, PDGFR, and VEGFRs (18). Sunitinib caused regression of various established tumor xenografts derived from human colon, lung, and breast cancers (19). In addition, we have found that sunitinib induced growth inhibition and apoptosis of GIST-T1 cells that possessed the activating mutation in exon 11 of c-KIT, in association with blockade of c-KIT (20). Recently, sunitinib has been approved by the U.S. Food and Drug Administration for the treatment of GIST and advanced renal cell carcinoma (21). Furthermore, sunitinib has been shown to be active against AML cells with FLT3-ITD in vitro and in vivo (22), and the synergistic growth inhibition of these cells occurred when sunitinib was combined with the conventional anticancer agent cytarabine or daunorubicin (23). A phase 1 clinical study showed the efficacy and tolerability of this compound in treatment of individuals with AML with mutation of FLT3, although remissions were partial and the duration of remissions was short (24).

The present study explored the effects of sunitinib on a wide variety of hematologic malignancies and found that it was active in leukemia cells with activating mutations in RTK. In addition, rapamycin analogue RAD001 potentiated the antiproliferative activity of sunitinib in these cells.

Materials and Methods

Reagents
Sunitinib and the rapamycin analogue RAD001 were provided by Pfizer (Kalamazoo, MI) and Novartis (Basel, Switzerland), respectively, and were dissolved in 100% DMSO (Burdick & Jackson, Muskegon, MI) to a stock concentration of 10–2 mol/L and stored at –80°C.

Cells
FLT3-ITD-expressing MV4-11, Bcr/Abl-expressing KU812 and K562, and FIP1L1/PDGFR{alpha}-expressing EOL-1 leukemia cells were obtained from American Type Culture Collection (Manassas, VA). Kasumi-1 cells, which possess Asn822Lys c-Kit mutation, were a kind gift from Dr. H. Asou (Hiroshima University, Hiroshima, Japan; ref. 25). The Bcr/Abl-expressing PALL-1 and PALL-2 lymphoblastic cells and Kcl-22 cells, which were established from chronic myeloid leukemia in blast crisis, were described elsewhere (26, 27). Leukemia cells from patients were freshly isolated as previously described (28).

FLT3 Genotyping
FLT3-ITD mutations were detected with the use of site-specific primers to exons 14 and 15 to amplify a 324-bp fragment in the wild-type FLT3 sequence. ITD mutations were detected by the appearance of a larger band in gel electrophoresis as previously described (24). To detect FLT3-D835 mutations, a 263-bp fragment was amplified by PCR. If the EcoRV-digested product produced two bands (148 and 115 bp), wild-type FLT3 sequences were present as described (8). The presence of an uncut 263 fragment following digestion indicated loss of the EcoRV site and a D835 mutation.

Thymidine Uptake Studies
DNA synthesis was measured by tritiated thymidine uptake [3H]TdR (Perkin-Elmer, Boston, MA). Cells (5 x 105/mL) were cultured with various concentrations of sunitinib or RAD001, either alone or in combination, for 2 days in 96-well plates. Cells were pulsed with [3H]TdR [0.5 µCi (0.185 MBq)/well] during the last 6 hours of a 48-hour culture, harvested onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, MA), and counted by with the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD). All experiments were done in triplicate and repeated at least thrice.

Apoptosis Assays
The ability of sunitinib to induce apoptosis of leukemia cells was measured with Annexin V-FITC apoptosis detection kit according to the instruction of the manufacturer (PharMingen, Inc., San Diego, CA).

Phosphorylation Analysis of PDGFR{alpha} and FLT3
Lysates from MV4-11 or EOL-1 cells were prepared as previously described (20) and were immunoprecipitated with anti-FLT3 antibody (C-18, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or PDGFR{alpha} (C-20; Santa Cruz Biotechnology) and protein G-Sepharose (Pierce, Rockford, IL). The precipitated samples were subjected to Western blot analysis as previously described (18). The membrane was sequentially probed with anti-phosphotyrosine (Cell Signaling, Beverly, MA) and anti-FLT3 (Santa Cruz Biotechnology) or anti-PDGFR{alpha} (Santa Cruz Biotechnology) antibodies.

Immunoblotting
Immunoblotting was done as previously described (28). Anti-p-Akt (Ser473) (Cell Signaling), Akt (Cell Signaling), anti-p-p70S6K (Thr389) (Cell Signaling), anti-p70S6K (Santa Cruz Biotechnology), anti-p-4E-BP-1 (Thr70) (Cell Signaling), anti-4E-BP-1 (Cell Signaling), anti-p-ERK (Tyr202/Tyr204) (Cell Signaling), anti-ERK (Cell Signaling), anti-p-STAT5 (Tyr694) (Cell Signaling), anti-STAT5 (Abcam, Cambridge, United Kingdom), anti-p-STAT3 (Tyr705) (Cell Signaling), anti-STAT3 (Cell Signaling), and anti-ß-actin (Santa Cruz Biotechnology) antibodies were used. The band intensities were measured by densitometry.

Data Analysis
The combination index of sunitinib and RAD001 in freshly isolated leukemia cells was calculated using the median effect method of Chou and Talalay (ref. 29; Calcusyn Software, Biosoft, Cambridge, United Kingdom). Combination index < 1 indicates synergy, combination index = 1 indicates an additive effect, and combination index > 1 indicates antagonism between the two agents.

Statistical Analysis
Statistical analysis was done to assess the difference between two groups under multiple conditions by one-way ANOVA followed by Bonferroni's multiple comparison tests using PRISM statistical analysis software (GraphPad Software, Inc., San Diego, CA).

Results

Sunitinib Induced Growth Arrest of a Variety of Hematologic Malignant Cells
To explore the antitumor effects of sunitinib on hematologic malignancies, we cultured a variety of hematologic malignant cells in the presence of sunitinib (0.001–10 µmol/L) for 2 days. Sunitinib profoundly inhibited the proliferation of FIP1L1/PDGFR{alpha}-expressing EOL-1, FLT3-ITD-expressing MV4-11, and Kasumi-1 cells, which possess gain-of-function mutation in the c-KIT (Asn822Lys), with IC50s of 4, 25, and 30 nmol/L, respectively, on the second day of culture, as measured by thymidine uptake (Table 1 ). In addition, sunitinib was active against various types of hematologic malignant cells, including Bcr/Abl-expressing Kcl-22, K562, KU812, PALL-1, and PALL-2 cells with IC50s ranging from 2.5 to 7.5 µmol/L (Table 1). On the other hand, myelomonocytic leukemia U937, primary effusion lymphoma BCBL-1, and human T-cell lymphotrophic virus-1–infected MT-1 and MT-2 cells were resistant to sunitinib (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. Inhibition of the proliferation of malignant hematopoietic cells by SU11248

 
Sunitinib Induced Growth Arrest of Freshly Isolated Leukemia Cells
We next explored whether sunitinib affected the survival of freshly isolated leukemia cells. We cultured cells in the presence of various concentrations of sunitinib (0.01–1 µmol/L). After 2 days, the proliferation was measured by thymidine uptake. FLT3 genotyping by PCR showed that 5 of 16 (31%) samples expressed FLT3-ITD (figure not shown) and 1 of 16 (6%) possessed an FLT3-D835 mutation (figure not shown; Table 2 ). Sunitinib profoundly inhibited the proliferation of freshly isolated leukemia cells with FLT3 mutations: 0.01 or 1 µmol/L sunitinib inhibited the proliferation of mutant FLT3-expressing cells (n = 6) by either 63 ± 8% or 80 ± 8%, respectively. On the other hand, the same concentrations of sunitinib (0.01 or 1 µmol/L) inhibited the proliferation of leukemia cells having a wild-type FLT3 (n = 10) by 6 ± 9% or 44 ± 23%, respectively (P = 0.0005; Fig. 1 ). Sunitinib (1 µmol/L, 48 hours) inhibited the proliferation of leukemia cells by >50% in 6 of 10 (60%) cases without mutations of FLT3, including one case of acute lymphoblastic leukemia (L2) with Philadelphia chromosome who relapsed after conventional chemotherapy with imatinib (Table 2). The cytogenetic analysis found t(9;22; q34;q11) as a single abnormality when the patient was diagnosed; however, the complicated abnormalities were found at relapse including add(8; q24), add(7; q34), add(3; p21), as well as add(19; p13). These aberrant chromosomal abnormalities might contribute to imatinib resistance. Our sequence analysis found no mutations in the imatinib-binding site of c-Abl (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2. Effect of SU11248 on freshly isolated acute leukemia cells

 

Figure 1
View larger version (11K):
[in this window]
[in a new window]
  		Figure 1. Effect of sunitinib on freshly isolated leukemia cells either with or without FLT3 mutations. [3H]Thymidine uptake study. Freshly isolated leukemia cells (1 x 106/mL) were plated in 96-well plates and cultured with various concentrations of sunitinib (0.01–1 µmol/L). After 2 d, proliferation was measured by [3H]thymidine uptake. The experiments were done in triplicate. Cytotoxic effects of sunitinib on leukemia cells with (n = 6) or without (n = 10) FLT3 mutation were compared. Statistical significance between two groups was determined by Student's t test.

 
Sunitinib Induced Apoptosis of Leukemia Cells
The ability of sunitinib to induce apoptosis was measured by Annexin V staining. Exposure of EOL-1 cells to sunitinib (2 or 4 nmol/L, 48 hours) induced either 21% or 41% of these cells to become Annexin V staining positive, and <5% of control cells were positive for Annexin V (Fig. 2A ; P < 0.05). Similarly, sunitinib (20 or 40 nmol/L, 48 hours) induced apoptosis of MV4-11 cells in a dose-dependent manner (Fig. 2B). Profound induction of apoptosis developed in Kasumi-1 and Bcr/Abl-expressing KU812, K562, PALL-1, and PALL-2 cells after their exposure to high concentration of sunitinib (2 µmol/L) for 48 hours (data not shown).


Figure 2
View larger version (44K):
[in this window]
[in a new window]
  		Figure 2. Annexin V binding. Cells (5 x 105/mL) were plated in 24-well plates and cultured with various concentrations of sunitinib. After 2 d, cells were harvested and Annexin V binding and propidium iodide staining were analyzed by FACScan. Bottom left quadrants, viable cells; bottom right quadrants, early apoptotic cells. Top right quadrants, nonviable, late apoptotic/necrotic cells. Results represent the mean of triplicate plates.

 
Sunitinib Inhibited Autophosphorylation of PDGFR{alpha} and FLT3 and Their Downstream Effectors in EOL-1 and MV4-11 Cells
Exposure of EOL-1 cells to sunitinib (2–8 nmol/L) for 1 hour blocked autophosphorylation of PDGFR{alpha} in a dose-dependent manner (Fig. 3A ) in conjunction with inactivation of its downstream effectors Akt, STAT3, and ERK, as measured by detection of the phosphorylated forms of these proteins by Western blot analysis (Fig. 3B). Similarly, sunitinib (10–40 nmol/L, 1 hour) inhibited autophosphorylation of FLT3 in MV4-11 cells in conjunction with down-regulation of p-ERK and p-Akt in these cells (Fig. 3C and D).


Figure 3
View larger version (27K):
[in this window]
[in a new window]
  		Figure 3. Sunitinib inhibits autophosphorylation of PDGFR{alpha} and MV4-11 and their downstream effectors in leukemia cells. Coimmunoprecipitation. EOL-1 (A) and MV4-11 cells (C) were cultured with various concentrations of sunitinib. After 1 h, cells were harvested and proteins were extracted. The PDGFR{alpha} (A) and FLT3 (C) proteins were immunoprecipitated and subjected to Western blot analyses. The membrane was probed sequentially with an anti-phosphotyrosine antibody (top) and an anti-PDGFR{alpha} (A) or anti-FLT3 (C; bottom) antibody. p-Ty, phosphotyrosine. Western blot analysis. EOL-1 (B) and MV4-11 cells (D) were cultured in the presence of sunitinib. After 1 h, cells were harvested and proteins were extracted and subjected to Western blot analysis. The polyvinylidene fluoride membrane was sequentially probed with antibodies to p-Akt (Ser473), p-STAT3 (Tyr705), p-STAT5 (Tyr694), p-ERK (Tyr202/Tyr204), Akt, STAT3, STAT5, ERK, and ß-actin, and band intensities were measured by densitometry.

 
RAD001 Enhanced the Ability of Sunitinib in Leukemia Cells
We explored whether rapamycin analogue RAD001, the inhibitor of mTOR that locates downstream of Akt, potentiated the ability of sunitinib to inhibit the growth of leukemia cells. RAD001 significantly enhanced the ability of sunitinib; 2 or 4 nmol/L sunitinib inhibited the proliferation of EOL-1 cells by 26 ± 3% or 50 ± 4%, respectively, on the second day of culture (Fig. 4A ). The effect of RAD001 (100 nmol/L) on growth of EOL-1 cells was negligible. Exposure of these cells to RAD001 (100 nmol/L) and sunitinib (2 or 4 nmol/L) inhibited the proliferation of these cells by 62 ± 6% and 84 ± 3%, respectively (P < 0.01; Fig. 4A). Similarly, RAD001 enhanced the ability of sunitinib to inhibit the growth of MV4-11, Kasumi, KU812, K562, and PALL-2 cells (Fig. 4B–F). We also explored the effect of RAD001 and sunitinib on freshly isolated leukemia cells. RAD001 (10 nmol/L, 48 hours) failed to inhibit the proliferation of leukemia cells from case #3. Sunitinib (1,000 nmol/L, 48 hours) inhibited their proliferation by only 17 ± 3%; however, when these cells were exposed to combination of sunitinib and RAD001 at the same concentration, their growth was inhibited by 33 ± 4% (P < 0.01; Fig. 4G). RAD001 also sensitized freshly isolated leukemia cells (cases #6 and #14) to growth inhibition mediated by sunitinib (Fig. 4G and H). Combination index values of RAD001 and sunitinib in case #14 were <1 (IC50, 0.3; IC75, 0.3; IC90, 0.4; Fig. 4I), indicating that combination of these compounds produced the synergistic growth inhibition of freshly isolated leukemia cells, as measured by the median effect method of Chou and Talalay (29).


Figure 4
Figure 4
View larger version (64K):
[in this window]
[in a new window]
  		Figure 4. Combination of sunitinib and RAD001 induces enhanced growth inhibition of leukemia cells. EOL-1 (A), MV4-11 (B), Kasumi-1 (C), KU812 (D), K562 (E), PALL-2 (F), and freshly isolated leukemia cells from case #3 (G), case #6 (H), and case #14 (J) were cultured with either sunitinib or RAD001, alone or in combination. After 2 d, proliferation was measured by [3H]thymidine uptake. Statistical significance was determined by one-way ANOVA followed by Bonferroni's multiple comparison tests. Columns, mean of three experiments done in triplicate; bars, SD. *, P < 0.01. RAD, RAD001. J, combination index of sunitinib and RAD001 in freshly isolated leukemia cells from case #14 was calculated using the median effect method. Combination index < 1 indicates synergy; combination index = 1 indicates an additive effect; and combination index > 1 indicates antagonism between the two agents.

 
Sunitinib and RAD001 Down-Regulated Levels of p-p70S6K and/or p-4E-BP-1 in Leukemia Cells
To explore whether the sunitinib- and RAD001-induced growth inhibition of leukemia cells was correlated with impaired mTOR signaling, we measured levels of the phosphorylated forms of mTOR targets, p70S6K and 4E-BP-1, after exposure of these cells to sunitinib and/or RAD001. Sunitinib (4 nmol/L, 1 hour) and RAD001 (100 nmol/L, 1 hour) down-regulated levels of p-p70S6K in EOL-1 cells by ~60% and 80%, respectively (Fig. 5A ). When these cells were exposed to the combination of both at the same concentration, levels of p-p70S6K decreased by 85% (Fig. 5A). Sunitinib (8 nmol/L, 1 hour) and RAD001 (100 nmol/L, 1 hour) alone down-regulated levels of p-4E-BP-1 by 40%. Combination of both decreased phosphorylation of 4E-BP-1 by 60% in these cells (Fig. 5A). Similarly, sunitinib and RAD001 decreased levels of p-p70S6K and p-4E-BP-1 in MV4-11, KU812, and PALL-2 cells (Fig. 5B, and data not shown). Combination of both further decreased levels of p-p70S6K and p-4E-BP-1 in these cells (Fig. 5B, and data not shown).


Figure 5
View larger version (24K):
[in this window]
[in a new window]
  		Figure 5. Sunitinib and RAD001 block mTOR signaling. EOL-1 (A) and MV4-11 (B) cells were cultured with either sunitinib or RAD001, alone or in combination. After 1 h, cells were harvested and proteins were extracted and subjected to Western blot analysis. The polyvinylidene fluoride membrane was sequentially probed with antibodies against p-p70S6K (Thr389), p-4E-BP-1 (Thr70), p70S6K, and 4E-BP-1, and band intensities were measured by densitometry.

 
Discussion

RTKs, including PDGFR{alpha}, FLT3, and c-KIT, are emerging as promising molecular targets of AML. Sunitinib profoundly inhibited the proliferation of EOL-1, MV4-11, and Kasumi-1 cells, which express activating RTK mutations in PDGFR{alpha}, FLT3, and c-KIT, respectively. In addition, sunitinib was more potent against freshly isolated leukemia cells with FLT3 mutations compared with those with wild-type FLT3 (Fig. 1), which was in line with the results of a phase 1 clinical study with sunitinib for individuals with AML (25); p.o. administration of sunitinib (50 or 75 mg) for 4 weeks followed by a 2-week rest period caused remission in all patients (n = 4) with mutations of FLT3. On the other hand, remission was induced in only 2 of 7 (29%) patients with wild-type FLT3. In this clinical study, 8 of 13 (62%) patients experienced treatment-related adverse events including grade 4 fatigue and hypertension, which was dose limiting. In addition, two patients experienced fatal bleeding in the lung and cerebrum, respectively. Mean duration of remissions induced by treatment with sunitinib was merely 3 months. Together with these observations, addition of other compound(s) to sunitinib should be considered.

The mTOR inhibitor rapamycin appeared as one of the attractive candidates in the adjuvant setting with protein kinase inhibitor. Previous studies showed that rapamycin enhanced the activity of imatinib and PKC412, an RTK inhibitor, in Bcr/Abl- or FLT3-ITD-expressing leukemia cells, respectively (30, 31). In this study, we found that the rapamycin analogue RAD001, which was shown to be active against AML cells in vitro (32), enhanced the antiproliferative activity of sunitinib in EOL-1, MV4-11, Kasumi-1, as well as Bcr/Abl-expressing lymphoblastic leukemia cells (Fig. 4A–F). In addition, RAD001 sensitized freshly isolated leukemia cells, which were relatively resistant to sunitinib (case #3; Fig. 5G). Interestingly, Bcr/Abl-expressing acute lymphoblastic leukemia cells from case #6, which relapsed after conventional chemotherapy with imatinib, responded to both sunitinib (1 µmol/L, 48 hours) and RAD001 (10 nmol/L, 48 hours). When these cells were exposed to combination of both analogues, growth inhibition was significantly enhanced compared with either compound alone (Fig. 5H).

Sunitinib inhibited autophosphorylation of PDGFR{alpha} and FLT3 in EOL-1 and MV4-11 cells, respectively, and blocked their downstream effectors Akt, STAT, and ERK (Fig. 3). Furthermore, sunitinib down-regulated levels of phosphorylated forms of the mTOR effectors p70S6K and 4E-BP-1 in these cells (Fig. 6 ). As we expected, RAD001 dephosphorylated p70S6K and 4E-BP-1 in leukemia cells; when RAD001 was combined with sunitinib, levels of the phosphorylated forms of these proteins further decreased compared with either compound alone (Fig. 5). mTOR may be a common target of both the RTK inhibitor and rapamycin. The enhanced blockade of this serine/threonine kinase signaling by combination of these compounds could result in the augmented growth inhibition of leukemia cells (Fig. 6).


Figure 6
View larger version (28K):
[in this window]
[in a new window]
  		Figure 6. Hypothesis of how sunitinib and RAD001 block proliferative signals mediated by activated protein tyrosine kinase/Akt/mTOR pathway.

 
We have recently explored the medicinal action of sunitinib and rapamycin in GIST-T1 cells. Both sunitinib and rapamycin blocked mTOR signaling and their combination caused the enhanced growth inhibition of GIST-T1 cells (22), which was consistent with the results shown in this study using leukemia cells.

Taken together, sunitinib may be useful for the treatment of individuals with leukemias possessing activating mutations in RTK; and the combination of sunitinib and RAD001 represents a promising novel treatment strategy.

Footnotes

Grant support: Ministry of Education, Culture Sports, Science, and Technology of Japan (T. Ikezoe), Uehara Memorial Foundation (T. Ikezoe), and NIH grants and the Inger Fund (H.P. Koeffler).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/ 7/06; revised 7/16/06; accepted 8/16/06.

References

  1. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345–64.[Free Full Text]
  2. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624–31.[CrossRef][Medline]
  3. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907–14.[Abstract/Free Full Text]
  4. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111:190–5.[CrossRef][Medline]
  5. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–9.[Abstract/Free Full Text]
  6. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:89–94.[Abstract/Free Full Text]
  7. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326–35.[Abstract/Free Full Text]
  8. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434–9.[Abstract/Free Full Text]
  9. Beghini A, Peterlongo P, Ripamonti CB, et al. c-Kit mutations in core binding factor leukemias. Blood 2000;95:726–7.[Free Full Text]
  10. Beghini A, Larizza L, Cairoli R, Morra E. c-Kit activating mutations and mast cell proliferation in human leukemia. Blood 1998;92:701–2.[Free Full Text]
  11. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002;3:157–63.[CrossRef][Medline]
  12. Cools J, Quentmeier H, Huntly BJ, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004;103:2802–5.[Abstract/Free Full Text]
  13. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–80.[Abstract/Free Full Text]
  14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.[Abstract/Free Full Text]
  15. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004;5:519–23.[CrossRef][Medline]
  16. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.[Abstract/Free Full Text]
  17. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420–4.[CrossRef][Medline]
  18. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116–9.[CrossRef][Medline]
  19. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.[Abstract/Free Full Text]
  20. Ikezoe T, Yang Y, Bandobashi K, Taguchi T, Koeffler HP, Taguchi H. Effect of SU11248, a class III receptor tyrosine kinase inhibitor, on GIST-T1 cells and enhancement of growth inhibition mediated by the inhibitors of PI3-K/Akt/mTOR signaling. AACR-NCI-EORTC International Conference 2005, Philadelphia, USA. (Abstr. B46).
  21. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006;5:279–80.[CrossRef][Medline]
  22. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597–605.[Abstract/Free Full Text]
  23. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004;104:4202–9.[Abstract/Free Full Text]
  24. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986–93.[Abstract/Free Full Text]
  25. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031–6.[Abstract/Free Full Text]
  26. Miyagi T, Ohyashiki J, Yamato K, Koeffler HP, Miyoshi I. Phenotypic and molecular analysis of Ph1-chromosome-positive acute lymphoblastic leukemia cell lines. Int J Cancer 1993;53:457–62.[Medline]
  27. Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983;1:105–17.[Abstract]
  28. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-{kappa} B signal pathways. Mol Cancer Ther 2005;4:578–86.[Abstract/Free Full Text]
  29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.[CrossRef][Medline]
  30. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716–22.[Abstract/Free Full Text]
  31. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004;101:3130–5.[Abstract/Free Full Text]
  32. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972–80.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
C. Nishioka, T. Ikezoe, J. Yang, A. Miwa, T. Tasaka, Y. Kuwayama, K. Togitani, H. P. Koeffler, and A. Yokoyama
Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
Blood, May 15, 2008; 111(10): 5086 - 5092.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. J. Hiles and J. M. Kolesar
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 123 - 131.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. F. Peterson, A. Boyapati, E.-Y. Ahn, J. R. Biggs, A. J. Okumura, M.-C. Lo, M. Yan, and D.-E. Zhang
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts
Blood, August 1, 2007; 110(3): 799 - 805.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Di Lorenzo
Sunitinib Malate and Multiple Receptor Tyrosine Kinases Inhibitors: Are They Also Novel Drugs for Chronic and Neurophatic Pain?
J. Clin. Oncol., July 1, 2007; 25(19): 2858 - 2859.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Ikezoe, J. Yang, C. Nishioka, T. Tasaka, A. Taniguchi, Y. Kuwayama, N. Komatsu, K. Bandobashi, K. Togitani, H. P. Koeffler, et al.
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia
Mol. Cancer Ther., June 1, 2007; 6(6): 1851 - 1857.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Taguchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Taguchi, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online